Veterinary Diagnostics Sub-Sector of Animal Care Industry is Generating Multiple Investment Targets: See Top Stock Picks from Nicholas Jansen of Raymond James & Associates in this Exclusive Interview

Wall Street Transcript

67 WALL STREET, New York - July 10, 2013 - The Wall Street Transcript has just published its Pet and Animal Care Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Improving Pet Acquisitions - Heightened Competition Among Medication Providers - Resiliency To Discretionary Spending Trends - Competition From Big-Box Retailers

Companies include: IDEXX Laboratories Inc. (IDXX), Abaxis Inc. (ABAX), Heska Corp. (HSKA), VCA Antech Inc. (WOOF), MWI Veterinary Supply, Inc. (MWIV), Henry Schein Inc. (HSIC), Patterson Companies Inc. (PDCO), Abbott Laboratories (ABT) and many others.

In the following excerpt from the Pet and Animal Care Report, an expert analyst discusses the outlook for the sector for investors:

TWST: How would you describe the competitive landscape for veterinary diagnostics companies?

Mr. Jansen: I would say it's a very competitive business in both the point-of-care and in the reference lab. IDEXX and VCA Antech are essentially the dominant players in the reference lab space, but there are some players who are trying to get into the reference lab market, like Abaxis. They've essentially opened up their first lab almost two years ago, but they're still relatively small in the grand scheme of things when you think about VCA and IDEXX having over $300 million of reference lab revenue each, and Abaxis having less than $8 million on an annualized basis today. So certainly it's a very competitive environment between IDEXX and VCA Antech, and there's some small competition starting to try to take some share away, but having limited amount of success so far.

In the point-of-care diagnostic space, certainly IDEXX has the lion's share of market; they have about 60% to 80% of the market share depending on which segment you're looking at. Abaxis is second, and Heska is a distant third. Certainly with the new distribution changes between IDEXX and one of their large national distributors, it's going to be...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments